Atreca to sell antibody-related assets and materials to Immunome for $12.5M | Seeking Alpha
Atreca (BCEL) Stock Price, News & Analysis
Atreca Stock Photos - Free & Royalty-Free Stock Photos from Dreamstime
BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc. | The AI Journal
BCEL Stock Price and Chart — OTC:BCEL — TradingView
Atreca, Inc. (BCEL) Stock Price, Quote & News - Stock Analysis
Atreca, Inc. (NASDAQ:BCEL) Short Interest Down 89.6% in February - Techdows News
BAKER BROS. ADVISORS LP Reduces Stake in Atreca Inc
Atreca : Failure to Satisfy Listing Rule - Form 8-K - MarketScreener
Press Releases | Atreca
Biotech company Atreca is winding down, but its antimalarial drug lives on with Gates Foundation hoping to save millions of lives - San Francisco Business Times
Atreca Stock Analysis: Will It Be Able to Continue the Uptrend?
Atreca Approaches A Major Go/No-Go Decision (NASDAQ:BCEL) | Seeking Alpha
Investor Relations | Atreca
BIG PRICE JUMP | $BCEL STOCK ANALYSIS | ATRECA STOCK : u/Foreign-Economist704
Form of Class B Common Stock Certificate of Atreca, Inc | Atreca, Inc. | Business Contracts | Justia
Atreca Inc - Class A Stock Forecast: down to 0.000000011 USD? - BCEL Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
Why Is Atreca (BCEL) Stock Up 85% Today? | InvestorPlace
BCEL - Atreca, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (OTCPK)
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37% | Nasdaq
Buy Atreca Stock - BCEL Stock Price Today & News - Public.com
Atreca, Inc. (BCEL) Stock Price, Quote & News - Stock Analysis
Atreca downsizes again to focus on antibody-drug conjugate programmes - Clinical Trials Arena
